@article{d0098a4e7060474b890436363b738093,
title = "Expanding the spectrum of MOG antibody disease",
keywords = "MOG, myelin oligodendrocyte glycoprotein, neuromyelitis optica (NMO)",
author = "Michael Levy",
note = "Funding Information: authorship, and/or publication of this article: G.M. served in an advisory board for Genentech/Roche. D.O. has received research support from National Multiple Sclerosis Society, National Institutes of Health, Patient-Centered Outcomes Research Institute, Race to Erase MS Foundation, Genentech, and Genzyme. He has also received consulting fees from Biogen Idec, Genentech/Roche, Genzyme, and Merck. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: G.M. is currently supported by the National Multiple Sclerosis Society Institutional Clinician Training Award ICT 0002. She has also received fellowship funding from Biogen Fellowship (Grant 6873P-FEL).",
year = "2020",
month = apr,
day = "1",
doi = "10.1177/1352458519841824",
language = "English (US)",
volume = "26",
pages = "515--516",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",
}